FBR & Co assumed coverage on shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) in a note issued to investors on Thursday. The brokerage set an “outperform” rating and a $16.00 price target on the biopharmaceutical company’s stock. FBR & Co’s price target points to a potential upside of 98.27% from the company’s previous close.

Several other brokerages also recently issued reports on ACHN. Leerink Swann reiterated a “hold” rating and issued a $9.00 target price on shares of Achillion Pharmaceuticals in a research note on Wednesday, May 25th. Robert W. Baird restated an “outperform” rating and set a $10.00 price objective on shares of Achillion Pharmaceuticals in a research report on Monday, June 6th. Chardan Capital began coverage on shares of Achillion Pharmaceuticals in a research report on Thursday, July 14th. They set a “sell” rating and a $4.00 price objective on the stock. JMP Securities upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $13.00 price objective on the stock in a research report on Thursday, July 7th. Finally, Jefferies Group restated a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $10.33.

Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 8.07 on Thursday. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of 164.69 and a beta of 2.21. Achillion Pharmaceuticals has a 1-year low of $5.57 and a 1-year high of $10.95. The company has a 50-day moving average of $8.57 and a 200-day moving average of $8.39.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. During the same quarter in the prior year, the company posted ($0.25) earnings per share. Analysts anticipate that Achillion Pharmaceuticals will post ($0.62) earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in ACHN. Principal Financial Group Inc. boosted its stake in shares of Achillion Pharmaceuticals by 1.2% in the second quarter. Principal Financial Group Inc. now owns 20,829 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 253 shares during the period. ProShare Advisors LLC boosted its stake in shares of Achillion Pharmaceuticals by 0.5% in the second quarter. ProShare Advisors LLC now owns 116,049 shares of the biopharmaceutical company’s stock worth $905,000 after buying an additional 524 shares during the period. Parametric Portfolio Associates LLC boosted its stake in shares of Achillion Pharmaceuticals by 2.9% in the second quarter. Parametric Portfolio Associates LLC now owns 32,787 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 937 shares during the period. Creative Planning boosted its stake in shares of Achillion Pharmaceuticals by 0.8% in the second quarter. Creative Planning now owns 133,175 shares of the biopharmaceutical company’s stock worth $1,039,000 after buying an additional 1,000 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its stake in shares of Achillion Pharmaceuticals by 1.6% in the first quarter. UBS Asset Management Americas Inc. now owns 66,998 shares of the biopharmaceutical company’s stock worth $517,000 after buying an additional 1,039 shares during the period. 79.43% of the stock is owned by institutional investors and hedge funds.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

5 Day Chart for NASDAQ:ACHN

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.